

## Special Issue

# Vaccination in a Post-Pandemic World

### Message from the Guest Editor

Immunization is one of the most significant discoveries of modern medicine. However, the effectiveness of medicine depends on its acceptance by the patient, which requires social acceptance. The COVID-19 pandemic has brought immunization to the forefront of discussions, including vaccination against COVID-19. Before the pandemic, most people associated vaccination only with childhood immunization, and many were unaware of the vaccines recommended for adults. While the pandemic has helped to initiate a global conversation on immunization for all age groups, it has also led to a rise in anti-vaccination groups and a decrease in vaccination interest among specific populations. Therefore, assessing the current willingness to receive vaccinations among pediatric and adult groups is important. It is also essential to use the post-pandemic period to increase immunization uptake in all age groups. This Special Issue aims to evaluate how the COVID-19 pandemic has impacted vaccination strategies, how the post-pandemic period can be utilized to build global confidence in vaccination and to assess the current levels of vaccine acceptance in each age group.

### Guest Editor

Dr. Mateusz Babicki

Department of Family Medicine, Wrocław Medical University, 51-141 Wrocław, Poland

### Deadline for manuscript submissions

closed (30 June 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/192104](https://mdpi.com/si/192104)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).